Sharechat Logo

CBD Oversubscription Bookbuild and Capital Raise Complete

Monday 12th September 2022

Text too small?

Cannasouth is pleased to announce that it has completed the Oversubscription Bookbuild component of its 1 for 10 pro rata renounceable rights offer ("Rights Offer”).

A total of $3,180,219 was raised under the Rights Offer and Oversubscription Bookbuild in aggregate.

The Oversubscription Bookbuild process was undertaken in respect of shares not taken up under the Rights Offer, including the shares attributable to Ineligible Shareholders.

The Oversubscription Price for new shares to be issued under the Oversubscription Bookbuild Facility was set at $0.30 by Cannasouth.

A total of 5,537,736 new shares are to be issued under the Oversubscription Bookbuild process at the Oversubscription Price.

Cannasouth Chair, Tony Ho, said: “The successful completion of our Renounceable Rights Issue, raising circa $3.2m from shareholders and wholesale investors demonstrated the strong support of our shareholders on our strategic plan in developing a world class medicinal cannabis company in New Zealand. On behalf of Team Cannasouth and the Board, I thank our shareholders and investors for their continuous support.”

Managing Director, Mark Lucas, added: “Cannasouth is committed to remain nimble footed in the evolving high growth global medicinal cannabis sector. The landscape is changing rapidly and we will continue to seek opportunities to grow and add value for our shareholders who have shown us great support in building the business to this point.”

Allotment of new shares

Settlement, allotment and trading in the new shares under the Rights Offer and the Oversubscription Bookbuild is expected to occur on or before 14 September 2022 under the existing ticker “CBD”.

-ENDS-

CBD Rights Issue - Closing of Bookbuild Announcement



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors
December 19th Morning Report
RAD - Radius Care Announces On-market Share Buyback Programme
MCY - New wind farm propels MCY renewables commitment to $1b